Gentronix Ltd further expands labs to meet growing demand

North West-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology CRO, has announced the next phase in its ongoing growth plan with the opening of a brand-new 2,819 sq. ft laboratory and office suite at Alderley Park, Cheshire.

Gentronix’s comprehensive growth strategy and rising global demand for its services have enabled it to increase capacity for its genetic toxicology studies and create more job opportunities for scientists in the North West of England.

The newly-established suite will accommodate the activities of the Big Blue® transgenic mutation workflow, which plays a key role in enabling risk assessments for materials where pre-existing data indicates a potential mutagenicity risk to human health and the environment.

The expansion has increased Gentronix’s footprint at Alderley Park by 30 per cent, strengthening its ability to support clients in meeting their regulatory requirements, identifying potential hazards within project pipelines, and managing risk for their materials.

This continued growth follows a previous successful expansion in 2021 to increase capacity of Gentronix’s genetic, ocular, and skin toxicology testing. The firm also recently strengthened its executive management team by appointing Derek McFerran as Chief Commercial Officer to help facilitate the business’s future growth ambitions.

CEO at Gentronix, Matt Tate, said: “We are delighted to be expanding our footprint within the Alderley Park Campus once again which has also allowed us to create more jobs for highly skilled scientists in the North West.

“This further expansion is an important part of our continued growth plan and will allow us to increase capacity to meet continuing market demands. We are able to support our clients with their genetic toxicology testing right from early-stage screening tests through to regulatory studies enabling human risk assessment.”

By Mark Adair – Correspondent, Bdaily